world
Warburg Pincus nears $7 billion deal for specialty pharmacy PANTHERx Rare
Private-equity firm Warburg Pincus is close to acquiring specialty-pharmacy company PANTHERx Rare in a transaction valued at more than $7 billion, including debt. The deal would transfer ownership of the company from its current investors.
Jul 10, 1:17 PM·1m read2 sources
news.sky.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Private-equity firm Warburg Pincus is near a deal to buy specialty-pharmacy company PANTHERx Rare for over $7 billion, including debt. The transaction would mark the exit for PANTHERx Rare's existing owners. No closing timeline or additional terms have been disclosed.
Rare operates a specialty pharmacy focused on rare-disease medications. Warburg Pincus invests across healthcare and other sectors. The reported purchase price exceeds $7 billion when debt is included. The companies have not confirmed whether regulatory approvals will be required.
Transparency
How sources framed this
These outlets didn't split into competing frames — coverage was uniform.
CorroborationModerate · 2 sources
